Subcutaneous pantoprazole in an elderly, palliative care patient.
Hugues MichelonHélène SouchuBénédicte Chauvron-DefilippiAnne LecoeurMaryvonne VillartMichel DenisPublished in: BMJ supportive & palliative care (2019)
Proton pump inhibitors (PPIs) have become the agents of choice for acid-related diseases. In some clinical situations, PPI therapy by oral or intravenous route may be difficult especially among elderly and patients in palliative care. Off-label PPI subcutaneous injection could be the last alternative to improve patient relief, despite limited published data. We report a case of linitis plastica, peritoneal carcinomatosis and occlusive syndrome who suffered from painful regurgitations which rapidly improved after subcutaneous pantoprazole. No related adverse effects were observed during PPI therapy. Despite some limitations, this report suggests that off-label subcutaneous pantoprazole could be an interesting alternative route when intravenous infusion may be difficult or harmful for elderly and patients in palliative care. Nevertheless, clinical safety and efficiency data on larger populations are needed to validate this use in such population.
Keyphrases
- palliative care
- end stage renal disease
- advanced cancer
- ejection fraction
- chronic kidney disease
- newly diagnosed
- middle aged
- case report
- peritoneal dialysis
- randomized controlled trial
- low dose
- protein protein
- patient reported outcomes
- big data
- artificial intelligence
- machine learning
- stem cells
- high dose
- bone marrow
- drug induced